SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, all datesinclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sar ...

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Pinterest CEO Bill Ready said Friday (Aug. 8) that it will be some time before consumers are ready to let artificial intelligence (AI) agents do their shopping for them, but that Pinterest is providing AI-powered tools that will “meet the user where they are” in the meantime.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form ...

Core Insights - Anbio Biotechnology has launched a Chikungunya IgM/IgG Rapid Test to enhance outbreak detection capabilities for mosquito-borne diseases, particularly in tropical and subtropical regions where cases are rising [1][2] - The company is also introducing the AP-100 Ultra-Fast PCR system, which significantly reduces testing time from hours to minutes while maintaining accuracy, aimed at improving decentralized molecular diagnostics [3][4] Group 1: Chikungunya Rapid Test - The Chikungunya IgM/IgG Rapid Test provides a fast and accessible diagnostic tool for clinicians and public health authorities, crucial for timely detection and differentiation from other arboviral infections like Dengue and Zika [1][2] - This test is based on immunochromatographic technology, allowing reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood [2] Group 2: AP-100 Ultra-Fast PCR System - The AP-100 system utilizes advanced microfluidic thermal cycling and high-efficiency enzymatic amplification, enabling direct processing of swab samples without nucleic acid extraction [4] - It is designed to be a flexible molecular platform, initially focused on respiratory infections but expanding to include tests for tuberculosis (TB) and human papillomavirus (HPV) [4] Group 3: Strategic Importance - Anbio's innovations in diagnostics aim to enhance healthcare capacity in both well-resourced and resource-limited settings, thereby advancing global preparedness for infectious disease threats [5] - The company emphasizes the need for diagnostics to keep pace with emerging health threats, reinforcing its commitment to rapid and reliable testing solutions [5] Group 4: Company Overview - Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company offering a wide range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, and rapid testing [6] - The company aims to enhance the availability of reliable and timely diagnostics to support better decision-making in healthcare settings worldwide [6]

Core Insights - First National Bank Alaska reported a net income of $18.4 million for Q2 2025, an increase from $15.6 million in Q2 2024, translating to earnings per share of $5.80 compared to $4.94 the previous year [1][2]. Financial Performance - The bank's return on assets improved to 1.46% as of June 30, 2025, marking a 38 basis points increase from the previous year [2][4]. - Total interest and loan fee income for Q2 2025 was $57.0 million, a 0.7% increase from $56.6 million in Q2 2024, with interest income from loans rising by $4.0 million [3]. - Total interest expense decreased to $11.8 million in Q2 2025, down from $16.5 million in Q2 2024, contributing to a net interest margin of 3.69%, up from 2.98% year-over-year [5]. Loan and Asset Quality - Total loans reached $2.6 billion as of June 30, 2025, an increase of $200.1 million from the previous year, while nonperforming loans rose to $9.8 million, representing 0.38% of total loans [2][13]. - The provision for credit losses for the year-to-date was $2.2 million, up from $1.3 million in the same period last year, reflecting loan growth [2]. Equity and Capital - Shareholders' equity increased to $550.1 million as of June 30, 2025, compared to $485.2 million a year earlier, with a return on equity of 13.53% [7]. - The bank's Tier 1 leverage capital ratio stood at 11.95%, well above the regulatory minimum [7][13]. Operational Efficiency - Noninterest operating income for Q2 2025 was $7.4 million, consistent with the previous year, while noninterest expenses rose by $1.4 million due to increased salaries and benefits [6]. - The efficiency ratio improved to 50.58%, outperforming peer groups both in Alaska and nationally [6].

Group 1 - Oneok Inc. reported $7.89 billion in revenue for Q2 2025, a year-over-year increase of 61.2%, with EPS of $1.34 compared to $1.33 a year ago [1] - The reported revenue was below the Zacks Consensus Estimate of $8.56 billion, resulting in a surprise of -7.91%, while the EPS met the consensus estimate [1] - Over the past month, Oneok's shares returned -6.7%, contrasting with the Zacks S&P 500 composite's +1.9% change, and the stock holds a Zacks Rank 3 (Hold) [3] Group 2 - Raw feed throughput for Natural Gas Liquids was 1,527.00 MBBL/d, below the average estimate of 1,702.67 MBBL/d [4] - Revenues from Natural Gas Gathering and Processing reached $1.85 billion, significantly exceeding the average estimate of $1.37 billion, representing a year-over-year change of +118.4% [4] - Revenues from Natural Gas Pipelines were $405 million, surpassing the estimated $161.26 million, with a year-over-year increase of +148.5% [4] - Revenues from Refined Products & Crude totaled $2.91 billion, well above the average estimate of $992.77 million [4] - Revenues from Natural Gas Liquids amounted to $3.87 billion, exceeding the average estimate of $3.06 billion, with a year-over-year change of +9.7% [4] - Adjusted EBITDA for Natural Gas Liquids was $673 million, slightly below the estimated $725 million [4] - Adjusted EBITDA for Refined Products & Crude was $557 million, slightly above the average estimate of $549.48 million [4] - Adjusted EBITDA for Natural Gas Pipelines reached $188 million, exceeding the average estimate of $145.59 million [4] - Adjusted EBITDA for Natural Gas Gathering and Processing was $540 million, in line with the average estimate of $538.82 million [4]

Core Viewpoint - Questerre Energy Corporation reported significant increases in production and revenue for the second quarter of 2025, driven by the tie-in of new wells, despite facing challenges from lower realized prices and higher expenses [2][4][5]. Production and Operations - Average daily production reached 3,091 barrels of oil equivalent per day (boe/d) for the quarter, nearly doubling from 1,559 boe/d in the same period last year [3][9]. - The company is assessing processing capacity for current and future production volumes and has scheduled a follow-up drilling program for the second half of next year [2]. Financial Performance - Petroleum and natural gas sales for the quarter totaled $13.7 million, up from $8.8 million in 2024, contributing to adjusted funds flow from operations of $5 million, compared to $4.5 million in the previous year [4][16]. - Net cash from operating activities was $6.3 million for the quarter, an increase from $3.1 million in 2024 [5][16]. Legal and Regulatory Developments - The company filed an application for leave to appeal a decision by the Quebec Court of Appeal regarding Bill 21, which is significant for protecting shareholders' rights [2][9]. Capital Expenditures and Financial Position - Capital expenditures for the quarter were $1 million, a decrease from $7 million in 2024, while year-to-date capital expenditures totaled $18.9 million compared to $9.7 million in the previous year [5]. - As of June 30, 2025, the company held unrestricted cash and term deposits of $18.3 million and had a net working capital surplus of $13.2 million [6][17].

Core Viewpoint - Questerre Energy Corporation reported significant increases in production and revenue for the second quarter of 2025, driven by the tie-in of new wells, while also facing challenges related to legal proceedings and fluctuating market prices [2][5][10]. Financial Performance - Average production for the quarter was 3,091 boe/d, nearly doubling from 1,559 boe/d in the same period last year [4][10]. - Petroleum and natural gas sales reached $13.7 million for the quarter, up from $8.8 million in 2024, and $22.8 million year-to-date compared to $17.8 million in 2024 [5]. - Adjusted funds flow from operations was $5 million for the quarter, an increase from $4.5 million in 2024, and $8.5 million year-to-date compared to $7.4 million in 2024 [5][17]. - Net cash from operating activities was $6.3 million for the quarter, up from $3.1 million in 2024 [6][17]. Production and Operations - The company is assessing processing capacity for current and future production volumes, with a follow-up drilling program planned for the second half of next year [2]. - Liquids production averaged 1,690 bbls/d for the quarter, compared to 931 bbls/d in 2024, while natural gas production was 8,409 Mcf/d, up from 3,767 Mcf/d in 2024 [13]. Legal and Regulatory Developments - The company filed an application for leave to appeal a decision by the Quebec Court of Appeal regarding Bill 21, which is crucial for protecting shareholder rights [2][10]. Cash Position - As of June 30, 2025, the company held unrestricted cash and term deposits of $18.3 million, with a net working capital surplus of $13.2 million [7].

Core Insights - The rapid advancement of humanoid robots is expected to lead to their integration into everyday life within a decade, as noted by Brett Adcock, founder of Figure AI [1][2] - The shift towards robotics in various sectors, including logistics and industrial operations, is already underway, with companies like Amazon and Walmart leading the way [3][4] - Innovations in robotics, such as self-replicating robots and living robots created from stem cells, indicate a future where robots can adapt and heal [5][6] Industry Trends - The AI and robotics sector is experiencing a significant transformation, comparable to the Industrial Revolution, with robots taking over physical tasks traditionally performed by humans [8][9] - Major tech companies are projected to spend over $400 billion on capital expenditures related to AI infrastructure in the coming year, a substantial increase from previous years [14][16] - Companies like Arista Networks and MP Materials are benefiting from this surge in AI infrastructure spending, with strong earnings reports reflecting ongoing investment in AI technologies [17][20] Investment Opportunities - The current landscape for humanoid robots is likened to the early 2000s smartphone market, suggesting significant investment potential as the technology matures [10][11] - The focus on AI infrastructure investments is expected to yield new AI models and services that will be rapidly adopted by enterprises and consumers [20][21] - Analysts recommend investing in companies positioned to benefit from the influx of capital into AI infrastructure, highlighting names like Arista Networks and MP Materials [19][20] Economic Outlook - The Federal Reserve is anticipated to implement a rate cut in September, which could influence market dynamics depending on the perception of the cut's rationale [22][24] - Economic indicators suggest a slowing economy, prompting discussions on the appropriateness of adjusting the federal funds rate [23][24]

Core Viewpoint - Scryb Inc. has provided an update regarding its holdings in Cybeats Technologies Corp, following a debt settlement transaction that involved the acquisition of common shares [1][2]. Group 1: Acquisition Details - On August 5, 2025, Scryb acquired 9,788,450 common shares of Cybeats in exchange for settling $978,845 of debt, as part of a larger transaction where Cybeats issued a total of 15,000,000 common shares to settle $1,500,000 of outstanding debt [2]. - The common shares acquired are subject to a hold period of four months and one day starting from the closing date of the transaction [2]. Group 2: Ownership Structure - Prior to the debt settlement, Scryb owned or controlled 64,643,500 common shares and 13,125,000 warrants, representing approximately 49.17% and 53.78% of the issued and outstanding common shares of Cybeats on an undiluted and partially diluted basis, respectively [4]. - After the debt settlement and accounting for other transactions, Scryb now owns or controls 74,431,950 common shares and 13,125,000 warrants, representing approximately 38.59% and 42.50% of the issued and outstanding common shares of Cybeats on an undiluted and partially diluted basis, respectively [5]. Group 3: Future Intentions - The acquisition of the securities was completed for investment purposes, and Scryb may adjust its ownership in Cybeats based on market conditions and other factors in the future [6].